Call for shingles vaccine to be free for over 65s and immunocompromised

A pathway for the shingles vaccine (Shingrix) to be reimbursed by the HSE for immunocompromised patients and for people aged over 65 should be prioritised, Fine Gael TDs have said.

Deputies Colm Burke and Barry Ward have highlighted that at present the HSE advises that shingles vaccination cannot be accessed through either the Medical Card or Drugs Payment Scheme.

Deputy Burke said: “Shingles can be an extremely painful and debilitating illness, particularly for older people and those whose immune systems are compromised.

“The risk and severity increase significantly with age, yet patients in Ireland currently have to pay privately for vaccination.

“I believe the HSE should work towards the introduction of a funded shingles vaccination programme for everyone aged 65 and over, as well as immunocompromised patients for whom vaccination is clinically appropriate.

“Ireland should examine the approach being taken internationally.

“In the UK, the NHS provides the vaccine for those aged 65 and older and several European countries, like Luxembourg, also provide it free for older people or high-risk groups.”

Irish data considered by HIQA in 2024 showed an average of 285 hospitalisations per year between 2013 and 2022 where shingles was the primary diagnosis, with almost three quarters involving people aged over 50.

There were also 54 deaths in acute hospitals during that period where shingles was the primary diagnosis.

Among people aged 80 and over who develop shingles, HIQA reported approximately a one in five risk of developing post-herpetic neuralgia, which can result in prolonged severe nerve pain.

Ireland’s National Immunisation Advisory Committee already recommends Shingrix for all adults aged 65 and over, as well as a range of immunocompromised patients, including those aged 50 and over with immunocompromising conditions and certain younger high-risk groups.

Deputy Barry Ward said: “I believe we should be prioritising the provision of HSE reimbursement from the age of 65 and over and for immunocompromised patients.

“For older people shingles can have serious, lasting consequences and it is essential that we look at methods of supporting them in their ageing.

“The vaccine is safe and effective.

“It is vital that the State develops a targeted programme focused on those who are most likely to benefit.

“Cost should not be the reason an older or clinically vulnerable person who would benefit from vaccination is unable to access it.

“A properly targeted and funded programme would improve access, prevent serious illness and help reduce avoidable pressure on our health services”.